Plain-English translation of NCT07462377 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1 — Testing in a small group (usually 20–80 people) to find a safe dose and watch for side effects.
This is one of the first times this treatment has been tested in people.
This is a first-in-human study of a new experimental drug called , designed to treat certain types of advanced lung cancer and head and neck cancer. Researchers want to understand how safe the medication is, how your body handles it, and whether it can slow or stop cancer growth. You would be among the first people to receive this treatment.
Current treatments don't work well enough for everyone with these cancers, especially those whose tumors have specific genetic mutations. This medication may offer a new option by targeting how cancer cells grow.
You likely qualify if…
You likely don't qualify if…
You would receive doses of the experimental medication, starting at a lower dose and potentially increasing over time as researchers learn it is safe. You would have regular clinic visits for blood tests, physical exams, and scans to monitor how the medication affects your cancer and your overall health. You would continue treatment until your cancer stops responding, you experience unacceptable side effects, or the study ends — which could be weeks to months depending on how your body responds.
AI-generated summary from trial data · Jul 17, 2026 · Not medical advice
United States